hoe-777 and Dermatitis--Seborrheic

We report on the results of an openly conducted multicenter study concerning efficacy and tolerance of a new prednisolone derivative free from halogenic groups (prednicarbate 0.25%, Dermatop) prepared as a) emulsifiable greasy ointment without water, b) w/o emulsion (ointment), and c) o/w emulsion (cream). These preparations were therapeutically applied in eczema (allergic, seborrheic, microbic), psoriasis, and atopic dermatitis. The study was carried out in close team work between a clinic and 37 practicing dermatologists and included 383 patients. After 3 weeks therapy, 4% of the patients did not reveal any satisfying results; 16% showed medium outcome with some persisting symptoms; in 80% of the patients, we observed good to very good therapeutic results.

Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Berlin; Child; Child, Preschool; Clinical Trials as Topic; Dermatitis; Dermatitis, Atopic; Dermatitis, Seborrheic; Eczema; Female; Humans; Male; Middle Aged; Pharmaceutical Vehicles; Prednisolone; Psoriasis

Prednicarbate (Dermatop) was topically applied in 50 children suffering from inflammatory dermatoses. In 12 children, the courses of therapy were documented by photographs. Its rapid onset of action, its lacking suppression of the endogenic biosynthesis of cortisol, as well as its small antiproliferative effect on cutaneous fibroblasts suggest that prednicarbate bears only minor risks especially for children's skin.

Topics: Administration, Topical; Anti-Inflammatory Agents; Child; Child, Preschool; Dermatitis; Dermatitis, Atopic; Dermatitis, Contact; Dermatitis, Seborrheic; Eczema; Female; Humans; Male; Prednisolone